The Clinic Efficacy And Prognosis Factor Analyse Of Decitabine Regimen In Treatment Of Myelodysplastic Syndromes In Medium-risk Group And High-risk Group

Objective:summarize The clinic efficacy and prognosis analyse of decitabine regimen in treatment Of Myelodysplastic Syndromes in in medium risk group and high risk group.Method:1.a retrospective analysis was used to analyze the data of 42patients diagnosed medium risk group and high risk group MDS patients hospitalized in First Affiliated Hospital of-University from January 1,2015 to January 1,2018 treated with decitabine regimen.Analyse their clinic efficacy and prognosis factor with to WHO 2008 standard,MDS diagnosis and treatment Chinese Expert Consensus(2014)and WHO adapted Prognostic Scoring System.According to MDS International work group(IWG)clinic efficacy standard,Monitor blood Hemoglobin,Neutrophil count,platelet count,Proportions of primordial cells in blood,Proportions of primordial cells in marrow,Abnormal morphology of blood cells.The results were divided into two groups of reaction group(gained therapeutic reaction)and no reaction group(no therapeutic reaction),of which 28 cases were in reaction group and 14cases in no reaction group.results were divided into two other groups of Complete remission and no Complete remission,of which 16 cases were in Complete remission group and 26 cases in no Complete remission group.2.Compare the physiological indexes of MDS patients with reaction group to no reaction group and Complete remission group to no Complete remission group:age and sexual distinction;clinical indicators:initial treatment and after treatment hemogram included blood Hemoglobin,Neutrophil count,platelet count,Proportions of primordial cells in blood,Proportions of primordial cells in marrow,Abnormal morphology of blood cells,Chromosome karyotype,Adverse reactions during treatment;prognostic indicators:WHO adapted Prognostic Scoring System(WPSS).Research the different between each two group to find influence of those factor in decitabine treatment MDS patient gained therapeutic reaction or Complete remission.3.Compare the physiological indexes of MDS patients whose Overall survival time>1 year to other patients,:age and sexual distinction;clinical indicators:initial treatment and after treatment hemogram included blood Hemoglobin,Neutrophil count,platelet count,Proportions of primordial cells in blood,Proportions of primordial cells in marrow,Abnormal morphology of blood cells,Chromosome karyotype,Adversereactionsduringtreatment;prognostic indicators:WHO adapted Prognostic Scoring System(WPSS),complete remission rate(CR),Overall Response Rate(ORR).Research the different between those patient to analysis indexes influence in decitabine treatment MDS patient’s Overall survival time.Results:After 2-8 course of decitabine treatment,28 patients gain treat reaction:CR 16 cases,PR 2 cases,HI 10cases,total effective rate66.7%.analyse of prognosis factor show patients with platelet count>100×10~9 can get higher CR rate;Analyse of survive time show patients whose OS≥1 year might relative with WPSS group,platelet count after 1course treatment,get CR and ORR(p<0.05)Conclusions:platelet count can forecast efficacy of decitabine treatment,WPSS group,platelet count after 1 course treatment,get CR and ORR influence patient’s prognosis.